Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 116.54% from the company’s previous close.

Separately, Wedbush reissued an “outperform” rating and set a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Trading Up 5.2 %

CMRX stock opened at $5.08 on Tuesday. The stock’s 50 day simple moving average is $3.68 and its 200 day simple moving average is $1.90. Chimerix has a 12-month low of $0.75 and a 12-month high of $5.53. The firm has a market cap of $456.90 million, a P/E ratio of -5.40 and a beta of 0.35.

Insider Activity

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by insiders.

Institutional Trading of Chimerix

A number of large investors have recently modified their holdings of CMRX. Bender Robert & Associates acquired a new position in Chimerix during the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix during the fourth quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix during the fourth quarter worth approximately $62,000. Diadema Partners LP bought a new position in Chimerix in the 4th quarter worth approximately $101,000. Finally, Squarepoint Ops LLC acquired a new stake in Chimerix in the 4th quarter valued at approximately $130,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.